Healthcare, Pharma & Life Sciences

FDA actions hit multiple gene therapy programs as uniQure, REGENXBIO, and Sarepta updates sharpen regulatory focus

Image
FDA actions hit multiple gene therapy programs as uniQure, REGENXBIO, and Sarepta updates sharpen regulatory focus

SHERIDAN, WYOMING - March 04, 2026 - A cluster of U.S. FDA-driven developments is reshaping near-term operating plans across gene therapy developers, with uniQure disclosing a new Phase 3 requirement, REGENXBIO facing a complete response letter for its Hunter syndrome program, and Sarepta Therapeutics managing a leadership change alongside conservative 2026 sales expectations for Elevidys. The same news cycle also includes broader questions from regulatory experts about how decisions are being made inside the agency, including scrutiny around CBER leadership. For clinical, regulatory, and finance teams, the immediate takeaway is execution risk: trial design expectations, control strategy, and evidentiary standards are moving targets that can directly change timelines and cost.

Teva taps $400M Blackstone financing to accelerate duvakitug development and de-risk late-stage execution with Sanofi

Image
Teva taps $400M Blackstone financing to accelerate duvakitug development and de-risk late-stage execution with Sanofi

SHERIDAN, WYOMING - March 04, 2026 - Teva has secured $400 million in funding from Blackstone Life Sciences to advance duvakitug, a Sanofi-partnered TL1A blocker in development for inflammatory bowel diseases. The financing is structured to be disbursed over four years and includes regulatory and undisclosed commercial milestones, plus low single-digit royalties on worldwide sales. For Teva, the deal adds non-dilutive-style runway and a clearer capital path for a program that already has defined Phase 3 responsibilities with Sanofi. For operators, it underscores how external capital is increasingly being used to sustain late-stage clinical programs while preserving strategic partnerships and commercialization options.

EveryONE Medicines shuts down, raising questions on FDA bespoke pathway scalability for ultra-small patient populations

Image
EveryONE Medicines shuts down, raising questions on FDA bespoke pathway scalability for ultra-small patient populations

SHERIDAN, WYOMING - March 04, 2026 - EveryONE Medicines has decided to close, shortly after the FDA released draft guidance intended to help drugmakers advancing personalized genetic medicines under a bespoke framework. Reporting cited an anonymous source who said the pathway was insufficient and difficult to work with for commercializing treatments aimed at exceedingly small patient populations, while a U.S. Department of Health and Human Services spokesperson rejected the idea that the FDA framework caused the shutdown. For rare-disease operators and investors, the development spotlights a core execution constraint in individualized medicines: whether regulatory expectations can be met repeatedly and economically when each therapy is effectively a one-off product.

Moderna settles Roivant-Arbutus lipid nanoparticle dispute to cap COVID-19 IP exposure and reduce legal overhang

Image
Moderna settles Roivant–Arbutus lipid nanoparticle dispute to cap COVID-19 IP exposure and reduce legal overhang

SHERIDAN, WYOMING - March 04, 2026 - Moderna has agreed to pay up to $2.25 billion to settle its patent conflict with Roivant and Arbutus Therapeutics over alleged use of protected lipid nanoparticle technology tied to its mRNA-based COVID-19 vaccine. The settlement terms include a $950 million upfront payment and up to $1.3 billion in contingent commitments linked to the outcome of an appeal aimed at limiting Moderna's liability through certain government-contractor immunity statutes. For executives and operators, the practical impact is risk containment: the agreement reduces uncertainty around potential multi-billion-dollar exposure, clarifies near-term cash obligations, and removes a material legal distraction as Moderna manages broader portfolio and regulatory priorities.

Sanofi licenses rovadicitinib from Sino Biopharm to expand global immunology pipeline with a Phase 2-ready oral asset

Image
Sanofi licenses rovadicitinib from Sino Biopharm to expand global immunology pipeline with a Phase 2–ready oral asset

SHERIDAN, WYOMING - March 04, 2026 - Sanofi has signed a worldwide licensing agreement with Sino Biopharmaceutical to secure global exclusive rights to rovadicitinib, an investigational oral small molecule positioned as an anti-inflammatory and anti-fibrotic therapy. The transaction includes a $135 million upfront payment and gives Sanofi the exclusive right to develop, manufacture, and commercialize the product globally, while Sino Biopharm is eligible for up to $1.395 billion in clinical, regulatory, and sales milestones plus double-digit tiered royalties. Operationally, the deal adds an oral candidate with a defined mechanism to Sanofi's immunology buildout and extends a pattern of external sourcing designed to accelerate portfolio depth without waiting for internal discovery timelines.

FDA Aftershock and Strategic Signals: What 2026 Could Mean for Regulated Industries

Image
FDA Aftershock and Strategic Signals: What 2026 Could Mean for Regulated Industries

SHERIDAN, WYOMING - February 10, 2026 - The U.S. Food and Drug Administration entered 2026 fundamentally reshaped after a year of unprecedented leadership turnover, shifting regulatory priorities, and workforce reductions under the second Trump administration. Developments throughout 2025 altered both risk profiles and opportunity structures for companies operating in pharmaceuticals, biologics, medical devices, and regulated food markets. For executives and regulatory leaders, understanding how these changes converged is now essential for planning submissions, investments, and compliance strategies in the year ahead.

Philips-Led PreciseOnco Consortium Secures IHI Funding to Advance Precision Cancer Interventions

Image
Philips-Led PreciseOnco Consortium Secures IHI Funding to Advance Precision Cancer Interventions

SHERIDAN, WYOMING - February 03, 2026 - Royal Philips has announced that the PreciseOnco research consortium, coordinated by Philips, has been awarded EUR 14.9 million in public funding from the European Union's Innovative Health Initiative (IHI) to accelerate the development of next-generation precision cancer treatments. The five-year program brings together advanced medical imaging, robotic guidance, and artificial intelligence to improve the safety, accuracy, and efficiency of minimally invasive cancer therapies. With additional in-kind and partner contributions, the total project budget reaches EUR 23.9 million, underscoring the scale and ambition of the initiative.

DIA Releases Full Agenda for 2026 Global Annual Meeting in Philadelphia

Image
DIA Releases Full Agenda for 2026 Global Annual Meeting in Philadelphia

SHERIDAN, WYOMING - February 03, 2026 - The Drug Information Association (DIA) has released the agenda for its 2026 Global Annual Meeting, providing the life sciences industry with an early view of the sessions, learning formats, and networking opportunities planned for the five-day event. Scheduled for June 14-18, 2026, in Philadelphia, Pennsylvania, the meeting is positioned as a major international convening point for professionals across drug development, regulation, clinical research, and healthcare innovation. With the agenda now available, attendees can begin building personalized schedules aligned with their functional roles and strategic priorities.

ALS Northwest Boosts 2025 Research Funding Through ALS United Collaboration to Accelerate ALS Breakthroughs

Image
ALS Northwest Wraps 2025 With a Bigger Bet on Research — and a Message of Urgency for Families

SHERIDAN, WYOMING - December 30, 2025 - ALS Northwest says it increased its financial investment in ALS research throughout 2025, expanding support for new approaches in treatment, prevention, and scientific understanding while joining a multi-organization funding initiative intended to strengthen the overall research pipeline.

Research investment strategy and portfolio focus

ALS Northwest framed its 2025 approach as a scaled-up commitment to research designed to accelerate innovation in amyotrophic lateral sclerosis (ALS). The organization said its efforts span multiple stages of scientific discovery, with an emphasis on enabling new approaches that could move the field forward. For research stakeholders, the operational question is not only how much is invested, but how efficiently funding is converted into validated findings, new targets, and ultimately clinical progress.